| Bladder cancer AM Kamat, NM Hahn, JA Efstathiou, SP Lerner, PU Malmström, W Choi, ... The Lancet 388 (10061), 2796-2810, 2016 | 1237 | 2016 |
| Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration V Margulis, SF Shariat, SF Matin, AM Kamat, R Zigeuner, E Kikuchi, ... Cancer 115 (6), 1224-1233, 2009 | 1111 | 2009 |
| Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline SS Chang, BH Bochner, R Chou, R Dreicer, AM Kamat, SP Lerner, ... The Journal of urology 198 (3), 552-559, 2017 | 847 | 2017 |
| Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018 MGK Cumberbatch, I Jubber, PC Black, F Esperto, JD Figueroa, ... European urology 74 (6), 784-795, 2018 | 752 | 2018 |
| CTLA-4 blockade increases IFNγ-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients CI Liakou, A Kamat, DN Tang, H Chen, J Sun, P Troncoso, C Logothetis, ... Proceedings of the National Academy of Sciences 105 (39), 14987-14992, 2008 | 602 | 2008 |
| Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial BC Carthon, JD Wolchok, J Yuan, A Kamat, DS Ng Tang, J Sun, G Ku, ... Clinical Cancer Research 16 (10), 2861-2871, 2010 | 532 | 2010 |
| Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer DJ McConkey, W Choi, L Marquis, F Martin, MB Williams, J Shah, ... Cancer and Metastasis Reviews 28, 335-344, 2009 | 423 | 2009 |
| Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group AM Kamat, RJ Sylvester, A Böhle, J Palou, DL Lamm, M Brausi, ... Journal of Clinical Oncology 34 (16), 1935, 2016 | 343 | 2016 |
| Focus on bladder cancer CPN Dinney, DJ McConkey, RE Millikan, X Wu, M Bar-Eli, L Adam, ... Cancer cell 6 (2), 111-116, 2004 | 340 | 2004 |
| Repeat transurethral resection in non–muscle-invasive bladder cancer: a systematic review MGK Cumberbatch, B Foerster, JWF Catto, AM Kamat, W Kassouf, ... European urology 73 (6), 925-933, 2018 | 295 | 2018 |
| Micropapillary bladder cancer: a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients AM Kamat, CPN Dinney, JR Gee, HB Grossman, AO Siefker‐Radtke, ... Cancer 110 (1), 62-67, 2007 | 293 | 2007 |
| Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, ... The Lancet Oncology 22 (7), 919-930, 2021 | 284 | 2021 |
| ZKSCAN3 is a master transcriptional repressor of autophagy S Chauhan, JG Goodwin, S Chauhan, G Manyam, J Wang, AM Kamat, ... Molecular cell 50 (1), 16-28, 2013 | 278 | 2013 |
| ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers AM Kamat, PK Hegarty, JR Gee, PE Clark, RS Svatek, N Hegarty, ... European urology 63 (1), 4-15, 2013 | 274 | 2013 |
| A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy … DJ McConkey, W Choi, YU Shen, IL Lee, S Porten, SF Matin, AM Kamat, ... European urology 69 (5), 855-862, 2016 | 271 | 2016 |
| Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial SA Boorjian, M Alemozaffar, BR Konety, ND Shore, LG Gomella, ... The lancet oncology 22 (1), 107-117, 2021 | 259 | 2021 |
| An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer GS Kulkarni, OW Hakenberg, JE Gschwend, G Thalmann, W Kassouf, ... European urology 57 (1), 60-70, 2010 | 248 | 2010 |
| The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma AM Kamat, JR Gee, CPN Dinney, HB Grossman, DA Swanson, ... The Journal of urology 175 (3), 881-885, 2006 | 247 | 2006 |
| Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort HM Fritsche, M Burger, RS Svatek, C Jeldres, PI Karakiewicz, G Novara, ... European urology 57 (2), 300-309, 2010 | 246 | 2010 |
| Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma SF Matin, V Margulis, A Kamat, CG Wood, HB Grossman, GA Brown, ... Cancer 116 (13), 3127-3134, 2010 | 242 | 2010 |
